20Slash20 Inc., the company behind The Eye Drink, announced its participation in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, scheduled for Sept. 9–10, 2026, in New York City. CEO Dr. Roger Wu is set to deliver an investor presentation at 9:35 a.m. ET on Sept. 9 at The Westin New York Grand Central, followed by one-on-one meetings with investors. This conference brings together growth companies, investors, and industry professionals across life sciences and emerging sectors, providing a platform for 20Slash20 to highlight its innovative approach to eye health.
The Eye Drink is positioned as the world's first ready-to-drink functional beverage formulated specifically with science-backed ingredients to support eye health for individuals who spend extended hours on digital devices. With the increasing prevalence of screen-induced eye problems, the product addresses a growing health concern in today's screen-centric world. The company emphasizes that the beverage offers a convenient and tasty solution, making it accessible for daily consumption.
The significance of this presentation lies in the potential investment and partnership opportunities that may arise from exposure to a targeted audience of investors and industry experts. As the functional beverage market continues to expand, particularly in the health and wellness sector, 20Slash20's participation could accelerate its growth trajectory. The conference serves as a critical venue for the company to communicate its value proposition and market potential.
According to the press release, the event will feature a range of companies in life sciences and other emerging industries, offering a diverse environment for networking and deal-making. For 20Slash20, this is an opportunity to secure funding, establish strategic alliances, and increase brand visibility among key stakeholders. The company's focus on eye health is particularly timely, given the global increase in digital device usage and the associated rise in conditions like digital eye strain.
The presentation at the Moody Capital Solutions conference underscores 20Slash20's commitment to advancing eye health through innovation. By engaging directly with investors, the company aims to demonstrate the scientific basis of its product and its commercial viability. The one-on-one meetings are expected to facilitate deeper discussions on potential collaborations and growth strategies.
More details about the conference and 20Slash20's participation can be found in the full press release at https://ibn.fm/tm2lT. For more information about 20Slash20 and The Eye Drink, interested parties can visit the company's official channels. The conference is set to be a pivotal moment for the company as it seeks to expand its footprint in the functional beverage market.
